183 filings
Page 7 of 10
8-K
r8l07589n02kwqlp
31 Aug 18
Departure of Directors or Certain Officers
12:00am
8-K
tke17myc2 ribbd8q
9 Aug 18
KemPharm, Inc. Reports Second Quarter 2018 Results
4:06pm
8-K
ql8mizrvg 1deyhirmc0
9 Aug 18
Regulation FD Disclosure
8:42am
8-K
ql18sdowy
9 Jul 18
KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD
7:05am
8-K
tfb0b2kp
11 Jun 18
Entry into a Material Definitive Agreement
4:29pm
8-K
fttpey mbzqdq3avo
24 May 18
Submission of Matters to a Vote of Security Holders
4:17pm
8-K
xpyc vfbef3xmzwnvf
10 May 18
KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results
4:33pm
8-K
q32nqy0 e7
29 Mar 18
KemPharm Reports Fourth Quarter and Year End 2017 Results
12:00am
8-K
kvik37tnxtn35
12 Mar 18
Other Events
12:00am
8-K
vdyzunw1fb8xqr
23 Feb 18
KemPharm Announces FDA Approval of Apadaz™ (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain
12:00am
8-K
3fnz3qms6idp4pj
31 Jan 18
Departure of Directors or Certain Officers
12:00am
8-K
36md1ec
9 Nov 17
KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update
12:00am
8-K
8exb50wmx
2 Oct 17
Other Events
12:00am
8-K
zytf5jfg3bhbvof3
26 Sep 17
Other Events
12:00am
8-K
ggxerh9n9japn4t58f
19 Sep 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
c271zrm639h8i71eaqum
12 Sep 17
KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDA
12:00am
8-K
eow1d
10 Aug 17
KemPharm, Inc. Reports Second Quarter 2017 Results
12:00am
8-K
y3v5ugfu
10 Aug 17
KemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial
12:00am
8-K
o8wfdewcj4y
28 Jun 17
KemPharm Strengthens ADHD Prodrug Pipeline with Development of KP484, A New, Super-Extended Release ADHD Methylphenidate Product Candidate
12:00am
8-K
kgeiq yvsd5hw7exp
23 May 17
Submission of Matters to a Vote of Security Holders
12:00am